NASDAQ:LXRX - Lexicon Pharmaceuticals Stock Price, Forecast & News

Lexicon Pharmaceuticals trades on the NASDAQ under the ticker symbol "LXRX."

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) posted its quarterly earnings results on Thursday, November, 7th. The biopharmaceutical company reported $2.11 EPS for the quarter, topping the consensus estimate of $1.31 by $0.80. The biopharmaceutical company earned $294.45 million during the quarter, compared to analysts' expectations of $12 million. Lexicon Pharmaceuticals had a net margin of 49.78% and a return on equity of 2,372.40%. The firm's quarterly revenue was up 4124.5% compared to the same quarter last year. During the same period last year, the company posted ($0.26) earnings per share. View Lexicon Pharmaceuticals' Earnings History.

Lexicon Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Lexicon Pharmaceuticals.

6 brokers have issued 12-month target prices for Lexicon Pharmaceuticals' stock. Their forecasts range from $3.00 to $17.00. On average, they anticipate Lexicon Pharmaceuticals' share price to reach $7.00 in the next year. This suggests a possible upside of 108.3% from the stock's current price. View Analyst Price Targets for Lexicon Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lexicon Pharmaceuticals in the last year. There are currently 5 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Lexicon Pharmaceuticals.

Media coverage about LXRX stock has trended extremely negative on Sunday, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lexicon Pharmaceuticals earned a coverage optimism score of -4.5 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Lexicon Pharmaceuticals.

Lexicon Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 13,580,000 shares, an increase of 17.8% from the December 31st total of 11,530,000 shares. Based on an average daily volume of 1,370,000 shares, the short-interest ratio is currently 9.9 days. Approximately 13.2% of the company's shares are short sold. View Lexicon Pharmaceuticals' Current Options Chain.

Some companies that are related to Lexicon Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Sarepta Therapeutics (SRPT), ACADIA Pharmaceuticals (ACAD), Dynavax Technologies (DVAX), MannKind (MNKD), Progenics Pharmaceuticals (PGNX), Orexigen Therapeutics (OREX), Iovance Biotherapeutics (IOVA), Geron (GERN) and Novavax (NVAX).

Lexicon Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Wedbush Securities Inc. (0.35%) and Strs Ohio (0.12%). Company insiders that own Lexicon Pharmaceuticals stock include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Institutional Ownership Trends for Lexicon Pharmaceuticals.

LXRX stock was sold by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. View Insider Buying and Selling for Lexicon Pharmaceuticals.

LXRX stock was purchased by a variety of institutional investors in the last quarter, including Strs Ohio. Company insiders that have bought Lexicon Pharmaceuticals stock in the last two years include Alexander A Santini, Christopher J Sobecki, James F Tessmer, Lonnel Coats, Public Equities LP Invus and Sam L Barker. View Insider Buying and Selling for Lexicon Pharmaceuticals.

Shares of LXRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of LXRX stock can currently be purchased for approximately $3.36.

Lexicon Pharmaceuticals has a market capitalization of $357.07 million and generates $63.21 million in revenue each year. The biopharmaceutical company earns $-120,550,000.00 in net income (profit) each year or ($1.14) on an earnings per share basis. Lexicon Pharmaceuticals employs 202 workers across the globe.View Additional Information About Lexicon Pharmaceuticals.

The official website for Lexicon Pharmaceuticals is http://www.lexpharma.com/.

Lexicon Pharmaceuticals' mailing address is 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS TX, 77381. The biopharmaceutical company can be reached via phone at 281-863-3000.